BioSpace News Archive

Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins, reported financial results and provided a business update for the three months ended September 30, 2023.

Theriva™ Biologics reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

IO Biotech announced the appointment of Helen Collins, MD, to its board of directors.

Aerovate Therapeutics, Inc. today announced financial results for the quarter ended September 30, 2023, and recent business highlights.

Comera Life Sciences Holdings, Inc. today announced it appointed Dorothy Clarke to its board of directors.

BioVie Inc. today announced positive clinical safety data from the Company’s Phase 2b open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, with standard of care (SOC) in patients with refractory ascites due to cirrhosis.

Intercept Pharmaceuticals, Inc. today announced new data from two Phase 2 studies, including a topline full data analysis (Study 747-213) and an interim analysis (Study 747-214), evaluating the effects of the investigational combination of farnesoid X receptor (FXR) agonist, obeticholic acid (OCA) and peroxisome proliferator-activated receptor (PPAR) agonist, bezafibrate, on multiple key serum biomarkers in primary biliary cholangitis (PBC) that have been shown to predict clinical outcomes.

Blueberry Therapeutics Limited announces that BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial in patients with onychomycosis, showing superiority over placebo with a high level of statistical significance.

Telix Pharmaceuticals Limited and Paris-based Mauna Kea Technologies, announce an expansion of the IRiS Alliance[1] through a strategic €6.0 million investment to develop new hybrid pharmaceutical-device products through the combination of Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio® surgical endomicroscopy platform.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the strategic strengthening of its medtech acceleration team with the appointment of Mano Iyer as Partner and the promotion of Cécile Dupont to Partner.